| |||||||||||||||||||
| These Coll1a1-TetO-MSI2 (Coll-TetO-MSI2) double targeted mutation mice have doxycycline (tetracycline) inducible overexpression of human MSI2 (musashi homolog 2) and may be useful in conjunction with other oncogenic mutations for studies of the role of MSI2 in proliferation and differentiation of hematopoietic stem and myeloid progenitor cells in diseases such as human leukemia. | |||||||||||||||||||
- Description
- Disease & phenotype
- Genes & alleles
- Genotyping
- Health & care
- References
- Pricing & purchasing
- Terms of use
Description
The genotypes of the animals provided may not reflect those discussed in the strain description or the mating scheme utilized by The Jackson Laboratory prior to cryopreservation. Please inquire for possible genotypes for this specific strain.
Strain Information
Type Congenic; Gene Trap; Mutant Strain; Targeted Mutation; Additional information on Genetically Engineered and Mutant Mice. Visit our online Nomenclature tutorial. Additional information on Congenic nomenclature. Species laboratory mouse Generation N6+F4pN1
Generation DefinitionsDonating Investigator Dr. Rudolf Jaenisch, Whitehead Institute (MIT) Description
These Coll1a1-TetO-MSI2 (Coll-TetO-MSI2) double mutant mice carry two targeted mutations: (1) an optimized form of reverse tetracycline controlled transactivator (rtTA*M2) in the Gt(ROSA)26Sor locus and (2) a tetracycline responsive element (tetO or TRE)-controlled human MSI2 (musashi homolog 2) gene in the Col1a1 locus. MSI2 plays a role in regulation of hematopoiesis. Aberrant MSI2 expression is associated with aggressive myeloid leukemia and poor prognosis in blast crisis chronic myelogenous leukemia. Doxycycline administration induces widespread overexpression of human MSI2 (musashi homolog 2), resulting in expansion of hematopoietic stem and progenitor cells. While mutant mice treated continuously with doxycycline for 1 year exhibit increased spleen and liver weights, and a reduction in MSI2 induction over time, they do not develop leukemia. Mice that are homozygous for the targeted mutations and untreated with doxycycline are viable, fertile, normal in size and do not display any gross physical or behavioral abnormalities. Recipient control mice transplanted with bone marrow from these Coll1a1-TetO-MSI2 double mutant mice exhibit (with doxycycline treatment) increased hematopoietic stem and progenitor cells, increased hematocrit and mean corpuscular volume; and decreased myeloid progenitor, myeloid erythroid progenitor cells, neutrophils, lymphocytes and platelets.Development
A targeting vector was designed to insert an optimized form of reverse tetracycline controlled transactivator (rtTA*M2) followed by a β-globin intron and polyA signal downstream of the Gt(ROSA)26Sor promoter. This construct was electroporated into (C57BL/6 x 129S4Sv/Jae)F1-derived V6.5 embryonic stem (ES) cells. Correctly targeted ES cells (called KH2) carrying the Gt(ROSA)26Sortm1(rtTA*M2)Jae allele, were retargeted to insert an FRT site-flanked PGK-Neo cassette and a promoterless hygromycin resistance cassette downstream of the Col1a1 locus. Correctly retargeted ES cells were selected and the FRT site-flanked PGK-Neo downstream of the Col1a1 locus was replaced by electroporating both a "flip-in plasmid" containing a PGK promoter, ATG start codon, FRT site, a splice acceptor-double polyA sequence, tetO (tetracycline responsive element) with a CMV minimal promoter, and SV40 polyA signal, upstream of the human MSI2 cDNA sequence, and a FLPe recombinase expressing vector to facilitate tetO-MSI2 recombination into the 3' UTR of the Col1a1 locus. The resulting correctly targeted ES cells, carrying rtTA*M2 in the Gt(ROSA)26Sor locus and tetO-MSI2 in the Col1a1 locus, were injected into recipient blastocysts. The mice were backcrossed to C57BL/6 for 5 generations. Upon arrival at The Jackson Laboratory, the mice were crossed to C57BL/6J (Stock No. 000664) at least once to establish the colony.
Control Information
| Control | ||
|---|---|---|
| 000664 C57BL/6J | ||
| Considerations for Choosing Controls | ||
Related Strains
Strains carrying Gt(ROSA)26Sortm1(rtTA*M2)Jae allele
View Strains carrying Gt(ROSA)26Sortm1(rtTA*M2)Jae (7 strains)
Additional Web Information
Tet Expression Systems
Phenotype
Phenotype Information
- Potential model based on gene homology relationships. Phenotypic similarity to the human disease has not been tested. Caffey Disease (COL1A1)
Collagen, Type I, Alpha-1; COL1A1 (COL1A1)
Ehlers-Danlos Syndrome, Type I (COL1A1)
Ehlers-Danlos Syndrome, Type VII, Autosomal Dominant (COL1A1)
Osteogenesis Imperfecta, Type I (COL1A1)
Osteogenesis Imperfecta, Type II (COL1A1)
Osteogenesis Imperfecta, Type III (COL1A1)
Osteogenesis Imperfecta, Type IV (COL1A1)
Osteoporosis (COL1A1)
assigned by genotype
The following phenotype information may relate to a genetic background differing from this JAX® Mice strain.
Col1A1tm6(tetO-MSI2)Jae/Col1a1+ Gt(ROSA)26Sortm1(rtTA*M2)Jae/Gt(ROSA)26Sor+
involves: 129S4/SvJae * C57BL/6
- mortality/aging
- increased sensitivity to induced morbidity/mortality
- wild-type mice reconstituted with bone marrow, treated with doxycyline, and transduced with BCR-ABL1 die within 14 days due to rapid and lethal myeloproliferative disease (MGI Ref ID J:163322)
- hematopoietic system phenotype
- abnormal bone marrow cell morphology/development (MGI Ref ID J:163322)
- decreased common myeloid progenitor cell number
- wild-type mice reconstituted with bone marrow and treated with doxycycline exhibit a decrease in myeloid progenitor and myeloid erythrocroid progenitor cells compared with mice reconstituted with wild-type bone marrow (MGI Ref ID J:163322)
- increased bone marrow cell number
- in wild-type mice reconstituted with bone marrow, treated with doxycyline, and transduced with BCR-ABL1 (MGI Ref ID J:163322)
- abnormal erythrocyte morphology (MGI Ref ID J:163322)
- increased erythrocyte cell number
- at 6 weeks, but not 16 weeks, in wild-type mice reconstituted with bone marrow and treated with doxycyline (MGI Ref ID J:163322)
- increased hematocrit
- at 6 and 16 weeks in wild-type mice reconstituted with bone marrow and treated with doxycyline (MGI Ref ID J:163322)
- increased mean corpuscular volume
- at 6 and 16 weeks in wild-type mice reconstituted with bone marrow and treated with doxycyline (MGI Ref ID J:163322)
- abnormal leukocyte morphology (MGI Ref ID J:163322)
- decreased lymphocyte cell number
- at 6 and 16 weeks in wild-type mice reconstituted with bone marrow and treated with doxycyline (MGI Ref ID J:163322)
- decreased neutrophil cell number
- at 16 weeks in wild-type mice reconstituted with bone marrow and treated with doxycyline (MGI Ref ID J:163322)
- increased leukocyte cell number
- in wild-type mice reconstituted with bone marrow, treated with doxycyline, and transduced with BCR-ABL1 (MGI Ref ID J:163322)
- abnormal myelopoiesis
- wild-type mice reconstituted with bone marrow, treated with doxycyline, and transduced with BCR-ABL1 die within 14 days due to rapid and lethal myeloproliferative disease (MGI Ref ID J:163322)
- decreased platelet cell number
- at 6 weeks, but not 16 weeks, in wild-type mice reconstituted with bone marrow and treated with doxycyline (MGI Ref ID J:163322)
- enlarged spleen
- wild-type mice reconstituted with bone marrow, treated with doxycyline, and transduced with BCR-ABL1 exhibit increased liver size compared with similarly treated mice reconstituted with wild-type bone marrow (MGI Ref ID J:163322)
- increased spleen weight
- spleen hyperplasia
- in wild-type mice reconstituted with bone marrow, treated with doxycyline, and transduced with BCR-ABL1 (MGI Ref ID J:163322)
- increased hematopoietic stem cell number
- doxycycline-treated mice exhibit an expansion of hematopoietic stem cells (HSCs) due to preferential expansion of short term HSC compared with wild-type mice (MGI Ref ID J:163322)
- wild-type mice reconstituted with bone marrow and treated with doxycycline exhibit an increase in HSCs, hematopoietic progenitor cells, and long term HSCs compared with mice reconstituted with wild-type bone marrow (MGI Ref ID J:163322)
- liver/biliary system phenotype
- increased liver weight
- tumorigenesis
- leukemia
- wild-type mice reconstituted with bone marrow, treated with doxycyline, and transduced with BCR-ABL1 exhibit an increase in the number of leukemic blasts and infiltration with immature myeloid cells compared with similarly treated wild-type mice reconstituted with wild-type bone marrow (MGI Ref ID J:163322)
- immune system phenotype
- abnormal leukocyte morphology (MGI Ref ID J:163322)
- decreased lymphocyte cell number
- at 6 and 16 weeks in wild-type mice reconstituted with bone marrow and treated with doxycyline (MGI Ref ID J:163322)
- decreased neutrophil cell number
- at 16 weeks in wild-type mice reconstituted with bone marrow and treated with doxycyline (MGI Ref ID J:163322)
- increased leukocyte cell number
- in wild-type mice reconstituted with bone marrow, treated with doxycyline, and transduced with BCR-ABL1 (MGI Ref ID J:163322)
- abnormal myelopoiesis
- wild-type mice reconstituted with bone marrow, treated with doxycyline, and transduced with BCR-ABL1 die within 14 days due to rapid and lethal myeloproliferative disease (MGI Ref ID J:163322)
- enlarged spleen
- wild-type mice reconstituted with bone marrow, treated with doxycyline, and transduced with BCR-ABL1 exhibit increased liver size compared with similarly treated mice reconstituted with wild-type bone marrow (MGI Ref ID J:163322)
- increased spleen weight
- spleen hyperplasia
- in wild-type mice reconstituted with bone marrow, treated with doxycyline, and transduced with BCR-ABL1 (MGI Ref ID J:163322)
This mouse can be used to support research in many areas including:
Cancer Research
Other
Research Tools
Cancer Research
Tetop Tet System
Genetics Research
Mutagenesis and Transgenesis: Tetop Tet System
Tet Expression Systems
tTA/rtTA Expressing Strains
tTA/rtTA Responsive Strains
Genes & Alleles
Gene & Allele Information provided by MGI
| Allele Symbol | Col1A1tm6(tetO-MSI2)Jae | ||
|---|---|---|---|
| Allele Name | targeted mutation 6, Rudolf Jaenisch | ||
| Allele Type | Targeted (knock-in) | ||
| Common Name(s) | Coll-TetO-MSI2; | ||
| Strain of Origin | (C57BL/6 x 129S4/SvJae)F1 | ||
| Site of Expression | MSI2 is normally expressed in hematopoietic stem cells. | ||
| Expressed Gene | tetO, tet operator, | ||
| Expressed Gene | MSI2, musashi RNA-binding protein 2, human | ||
| General Note | The allele was made in KH2 cells that carry Gt(ROSA)26Sortm1(rtTA*M2)Jae and Col1a1tm2(tetO-Pou5f1)Jae. | ||
| Molecular Note | RMCE on KH2 cells inserted a cassette that contains a tetracycline operator and minimal CMV promoter drives inducible expression of the human cDNA preceded by a splice acceptor and polyadenylation sequence and followed by an FRT flanked PGK-neo cassette and promotorless hygro cassette into the 3'UTR. [MGI Ref ID J:163322] | ||
| Gene Symbol and Name | Col1a1, collagen, type I, alpha 1 | ||
| Chromosome | 11 | ||
| Gene Common Name(s) | COLIA1; Col1a-1; Cola-1; Cola1; Moloney leukemia virus 13; Mov-13; OI4; | ||
| Allele Symbol | Gt(ROSA)26Sortm1(rtTA*M2)Jae | ||
| Allele Name | targeted mutation 1, Rudolf Jaenisch | ||
| Allele Type | Targeted (knock-in) | ||
| Common Name(s) | Gt(ROSA)26Sortm1(M2rtTA)Jae; R26-M2rtTA; R26-rtTA; Rosa26-rtRA-nls; | ||
| Mutation Made By | Dr. Rudolf Jaenisch, Whitehead Institute (MIT) | ||
| Strain of Origin | (C57BL/6 x 129S4/SvJae)F1 | ||
| ES Cell Line Name | v6.5 | ||
| ES Cell Line Strain | (C57BL/6 x 129S4/SvJae)F1 | ||
| Site of Expression | Expresses an optimized rtTA protein (rtTA-M2). Inducible target gene expression is detected in liver, bone marrow, stomach, intestine, and skin, with lower levels in the heart, lungs, kidney, spleen, and thymus; no expression is detected in the brain and testes. | ||
| Expressed Gene | rtTA, reverse tetracycline-controlled transactivator, E. coli | ||
| The tetracycline repressor gene (Tetr), arose from chemically mutated Escherichia coli genome which was screened for tetracycline dependence (Gossen and Bujard, 1992). One mutant with a four amino acid residue change (rTetR) exhibited dependence on tetracycline for induction of the targeted gene and was used in the rtTA construct (Gossen et al, 1995). rTetr was fused at the C-terminus with the viral co-activator, virion protein 16 of the herpes simplex virus (VP-16). | |||
| General Note | This mutation was originally created downstream of the Col1a1tm2(tetO-Pou5f1)Jae allele in mutant ES cell line KH2 but the two mutations have subsequently been bred apart. | ||
| Molecular Note | An optimized form of reverse tetracycline controlled transactivator (rtTA-M2) was inserted downstream of the Gt(ROSA)26Sor promoter. This mutant form of rtTA termed M2 has five amino acid substitutions in the tetR moiety of tTA: S12G, E19G, A56P, D148E and H179R. This mutated form of transactivatory protein has increased doxycycline sensitivity. Mice have widespread expression of the rtTA-M2 protein. [MGI Ref ID J:98920] | ||
| Gene Symbol and Name | Gt(ROSA)26Sor, gene trap ROSA 26, Philippe Soriano | ||
| Chromosome | 6 | ||
| Gene Common Name(s) | AV258896; Gtrgeo26; Gtrosa26; R26; ROSA26; beta geo; expressed sequence AV258896; gene trap ROSA 26; gene trap ROSA b-geo 26; | ||
Genotyping
Genotyping Information
Genotyping Protocols
Col1a1 3'UTR assay2 (flip-in), Separated PCR
Helpful Links
Genotyping resources and troubleshooting
References
References provided by MGI
Selected Reference(s)
Kharas MG; Lengner CJ; Al-Shahrour F; Bullinger L; Ball B; Zaidi S; Morgan K; Tam W; Paktinat M; Okabe R; Gozo M; Einhorn W; Lane SW; Scholl C; Frohling S; Fleming M; Ebert BL; Gilliland DG; Jaenisch R; Daley GQ. 2010. Musashi-2 regulates normal hematopoiesis and promotes aggressive myeloid leukemia. Nat Med 16(8):903-8. [PubMed: 20616797] [MGI Ref ID J:163322]
Additional References
Gt(ROSA)26Sortm1(rtTA*M2)Jae relatedAoki H; Hara A; Era T; Kunisada T; Yamada Y. 2012. Genetic ablation of Rest leads to in vitro-specific derepression of neuronal genes during neurogenesis. Development 139(4):667-77. [PubMed: 22241837] [MGI Ref ID J:181188]
Beard C; Hochedlinger K; Plath K; Wutz A; Jaenisch R. 2006. Efficient method to generate single-copy transgenic mice by site-specific integration in embryonic stem cells. Genesis 44(1):23-8. [PubMed: 16400644] [MGI Ref ID J:159351]
Brambrink T; Foreman R; Welstead GG; Lengner CJ; Wernig M; Suh H; Jaenisch R. 2008. Sequential expression of pluripotency markers during direct reprogramming of mouse somatic cells. Cell Stem Cell 2(2):151-9. [PubMed: 18371436] [MGI Ref ID J:149805]
Brennand K; Huangfu D; Melton D. 2007. All beta Cells Contribute Equally to Islet Growth and Maintenance. PLoS Biol 5(7):e163. [PubMed: 17535113] [MGI Ref ID J:124045]
Camargo FD; Gokhale S; Johnnidis JB; Fu D; Bell GW; Jaenisch R; Brummelkamp TR. 2007. YAP1 increases organ size and expands undifferentiated progenitor cells. Curr Biol 17(23):2054-60. [PubMed: 17980593] [MGI Ref ID J:141457]
Carey BW; Markoulaki S; Beard C; Hanna J; Jaenisch R. 2010. Single-gene transgenic mouse strains for reprogramming adult somatic cells. Nat Methods 7(1):56-9. [PubMed: 20010831] [MGI Ref ID J:157298]
Dickins RA; McJunkin K; Hernando E; Premsrirut PK; Krizhanovsky V; Burgess DJ; Kim SY; Cordon-Cardo C; Zender L; Hannon GJ; Lowe SW. 2007. Tissue-specific and reversible RNA interference in transgenic mice. Nat Genet 39(7):914-21. [PubMed: 17572676] [MGI Ref ID J:123006]
Foudi A; Hochedlinger K; Van Buren D; Schindler JW; Jaenisch R; Carey V; Hock H. 2009. Analysis of histone 2B-GFP retention reveals slowly cycling hematopoietic stem cells. Nat Biotechnol 27(1):84-90. [PubMed: 19060879] [MGI Ref ID J:172421]
Gros J; Hu JK; Vinegoni C; Feruglio PF; Weissleder R; Tabin CJ. 2010. WNT5A/JNK and FGF/MAPK pathways regulate the cellular events shaping the vertebrate limb bud. Curr Biol 20(22):1993-2002. [PubMed: 21055947] [MGI Ref ID J:166897]
Guo S; Bai H; Megyola CM; Halene S; Krause DS; Scadden DT; Lu J. 2012. Complex oncogene dependence in microRNA-125a-induced myeloproliferative neoplasms. Proc Natl Acad Sci U S A 109(41):16636-41. [PubMed: 23012470] [MGI Ref ID J:190324]
He S; Kim I; Lim MS; Morrison SJ. 2011. Sox17 expression confers self-renewal potential and fetal stem cell characteristics upon adult hematopoietic progenitors. Genes Dev 25(15):1613-27. [PubMed: 21828271] [MGI Ref ID J:174416]
Heinonen KM; Vanegas JR; Brochu S; Shan J; Vainio SJ; Perreault C. 2011. Wnt4 regulates thymic cellularity through the expansion of thymic epithelial cells and early thymic progenitors. Blood 118(19):5163-73. [PubMed: 21937690] [MGI Ref ID J:178890]
Hirata A; Utikal J; Yamashita S; Aoki H; Watanabe A; Yamamoto T; Okano H; Bardeesy N; Kunisada T; Ushijima T; Hara A; Jaenisch R; Hochedlinger K; Yamada Y. 2013. Dose-dependent roles for canonical Wnt signalling in de novo crypt formation and cell cycle properties of the colonic epithelium. Development 140(1):66-75. [PubMed: 23222438] [MGI Ref ID J:191050]
Hochedlinger K; Yamada Y; Beard C; Jaenisch R. 2005. Ectopic expression of Oct-4 blocks progenitor-cell differentiation and causes dysplasia in epithelial tissues. Cell 121(3):465-77. [PubMed: 15882627] [MGI Ref ID J:98920]
Holl D; Kuckenberg P; Woynecki T; Egert A; Becker A; Huss S; Stabenow D; Zimmer A; Knolle P; Tolba R; Fischer HP; Schorle H. 2011. Transgenic Overexpression of Tcfap2c/AP-2gamma Results in Liver Failure and Intestinal Dysplasia. PLoS One 6(7):e22034. [PubMed: 21779369] [MGI Ref ID J:174049]
Jaako P; Flygare J; Olsson K; Quere R; Ehinger M; Henson A; Ellis S; Schambach A; Baum C; Richter J; Larsson J; Bryder D; Karlsson S. 2011. Mice with ribosomal protein S19 deficiency develop bone marrow failure and symptoms like patients with Diamond-Blackfan anemia. Blood 118(23):6087-96. [PubMed: 21989989] [MGI Ref ID J:179085]
Jansson L; Larsson J. 2012. Normal hematopoietic stem cell function in mice with enforced expression of the Hippo signaling effector YAP1. PLoS One 7(2):e32013. [PubMed: 22363786] [MGI Ref ID J:185310]
Jarde T; Evans RJ; McQuillan KL; Parry L; Feng GJ; Alvares B; Clarke AR; Dale TC. 2013. In vivo and in vitro models for the therapeutic targeting of Wnt signaling using a Tet-ODeltaN89beta-catenin system. Oncogene 32(7):883-93. [PubMed: 22469981] [MGI Ref ID J:193365]
Laplante M; Horvat S; Festuccia WT; Birsoy K; Prevorsek Z; Efeyan A; Sabatini DM. 2012. DEPTOR Cell-Autonomously Promotes Adipogenesis, and Its Expression Is Associated with Obesity. Cell Metab 16(2):202-12. [PubMed: 22883231] [MGI Ref ID J:187378]
Linhart HG; Lin H; Yamada Y; Moran E; Steine EJ; Gokhale S; Lo G; Cantu E; Ehrich M; He T; Meissner A; Jaenisch R. 2007. Dnmt3b promotes tumorigenesis in vivo by gene-specific de novo methylation and transcriptional silencing. Genes Dev 21(23):3110-22. [PubMed: 18056424] [MGI Ref ID J:127808]
Lopez ME; Klein AD; Dimbil UJ; Scott MP. 2011. Anatomically defined neuron-based rescue of neurodegenerative niemann-pick type C disorder. J Neurosci 31(12):4367-78. [PubMed: 21430138] [MGI Ref ID J:170312]
Lopez ME; Klein AD; Hong J; Dimbil UJ; Scott MP. 2012. Neuronal and epithelial cell rescue resolves chronic systemic inflammation in the lipid storage disorder Niemann-Pick C. Hum Mol Genet 21(13):2946-60. [PubMed: 22493001] [MGI Ref ID J:184610]
Magnusson M; Brun AC; Miyake N; Larsson J; Ehinger M; Bjornsson JM; Wutz A; Sigvardsson M; Karlsson S. 2007. HOXA10 is a critical regulator for hematopoietic stem cells and erythroid/megakaryocyte development. Blood 109(9):3687-96. [PubMed: 17234739] [MGI Ref ID J:145322]
Markoulaki S; Hanna J; Beard C; Carey BW; Cheng AW; Lengner CJ; Dausman JA; Fu D; Gao Q; Wu S; Cassady JP; Jaenisch R. 2009. Transgenic mice with defined combinations of drug-inducible reprogramming factors. Nat Biotechnol 27(2):169-71. [PubMed: 19151700] [MGI Ref ID J:158492]
McJunkin K; Mazurek A; Premsrirut PK; Zuber J; Dow LE; Simon J; Stillman B; Lowe SW. 2011. Reversible suppression of an essential gene in adult mice using transgenic RNA interference. Proc Natl Acad Sci U S A 108(17):7113-8. [PubMed: 21482754] [MGI Ref ID J:171348]
Paliwal P; Conboy IM. 2011. Inhibitors of tyrosine phosphatases and apoptosis reprogram lineage-marked differentiated muscle to myogenic progenitor cells. Chem Biol 18(9):1153-66. [PubMed: 21944754] [MGI Ref ID J:190199]
Petrelli A; Carvello M; Vergani A; Lee KM; Tezza S; Du M; Kleffel S; Chengwen L; Mfarrej BG; Hwu P; Secchi A; Leonard WJ; Young D; Sayegh MH; Markmann JF; Zajac AJ; Fiorina P. 2011. IL-21 is an antitolerogenic cytokine of the late-phase alloimmune response. Diabetes 60(12):3223-34. [PubMed: 22013017] [MGI Ref ID J:191409]
Premsrirut PK; Dow LE; Kim SY; Camiolo M; Malone CD; Miething C; Scuoppo C; Zuber J; Dickins RA; Kogan SC; Shroyer KR; Sordella R; Hannon GJ; Lowe SW. 2011. A rapid and scalable system for studying gene function in mice using conditional RNA interference. Cell 145(1):145-58. [PubMed: 21458673] [MGI Ref ID J:171191]
Quere R; Andradottir S; Brun AC; Zubarev RA; Karlsson G; Olsson K; Magnusson M; Cammenga J; Karlsson S. 2011. High levels of the adhesion molecule CD44 on leukemic cells generate acute myeloid leukemia relapse after withdrawal of the initial transforming event. Leukemia 25(3):515-26. [PubMed: 21116281] [MGI Ref ID J:170242]
Sehrawat S; Koenig PA; Kirak O; Schlieker C; Fankhauser M; Ploegh HL. 2013. A catalytically inactive mutant of the deubiquitylase YOD-1 enhances antigen cross-presentation. Blood 121(7):1145-56. [PubMed: 23243279] [MGI Ref ID J:194608]
Stadtfeld M; Maherali N; Borkent M; Hochedlinger K. 2010. A reprogrammable mouse strain from gene-targeted embryonic stem cells. Nat Methods 7(1):53-5. [PubMed: 20010832] [MGI Ref ID J:159350]
Takiguchi M; Dow LE; Prier JE; Carmichael CL; Kile BT; Turner SJ; Lowe SW; Huang DC; Dickins RA. 2013. Variability of inducible expression across the hematopoietic system of tetracycline transactivator transgenic mice. PLoS One 8(1):e54009. [PubMed: 23326559] [MGI Ref ID J:195871]
Tumaneng K; Schlegelmilch K; Russell RC; Yimlamai D; Basnet H; Mahadevan N; Fitamant J; Bardeesy N; Camargo FD; Guan KL. 2012. YAP mediates crosstalk between the Hippo and PI(3)K-TOR pathways by suppressing PTEN via miR-29. Nat Cell Biol 14(12):1322-9. [PubMed: 23143395] [MGI Ref ID J:195253]
Wan M; Gu H; Wang J; Huang H; Zhao J; Kaundal RK; Yu M; Kushwaha R; Chaiyachati BH; Deerhake E; Chi T. 2013. Inducible mouse models illuminate parameters influencing epigenetic inheritance. Development 140(4):843-52. [PubMed: 23325759] [MGI Ref ID J:194064]
Wan M; Kaundal R; Huang H; Zhao J; Yang X; Chaiyachati BH; Li S; Chi T. 2013. A general approach for controlling transcription and probing epigenetic mechanisms: application to the CD4 locus. J Immunol 190(2):737-47. [PubMed: 23293358] [MGI Ref ID J:191711]
Watanabe S; Hirai H; Asakura Y; Tastad C; Verma M; Keller C; Dutton JR; Asakura A. 2011. MyoD gene suppression by Oct4 is required for reprogramming in myoblasts to produce induced pluripotent stem cells. Stem Cells 29(3):505-16. [PubMed: 21425413] [MGI Ref ID J:175957]
Wesemann DR; Portuguese AJ; Magee JM; Gallagher MP; Zhou X; Panchakshari RA; Alt FW. 2012. Reprogramming IgH isotype-switched B cells to functional-grade induced pluripotent stem cells. Proc Natl Acad Sci U S A 109(34):13745-50. [PubMed: 22869756] [MGI Ref ID J:188595]
Yamada K; Ohno T; Aoki H; Semi K; Watanabe A; Moritake H; Shiozawa S; Kunisada T; Kobayashi Y; Toguchida J; Shimizu K; Hara A; Yamada Y. 2013. EWS/ATF1 expression induces sarcomas from neural crest-derived cells in mice. J Clin Invest :. [PubMed: 23281395] [MGI Ref ID J:194505]
Yamada Y; Aoki H; Kunisada T; Hara A. 2010. Rest promotes the early differentiation of mouse ESCs but is not required for their maintenance. Cell Stem Cell 6(1):10-5. [PubMed: 20085738] [MGI Ref ID J:157076]
Zhu H; Shah S; Shyh-Chang N; Shinoda G; Einhorn WS; Viswanathan SR; Takeuchi A; Grasemann C; Rinn JL; Lopez MF; Hirschhorn JN; Palmert MR; Daley GQ. 2010. Lin28a transgenic mice manifest size and puberty phenotypes identified in human genetic association studies. Nat Genet 42(7):626-30. [PubMed: 20512147] [MGI Ref ID J:166568]
Zhu H; Shyh-Chang N; Segre AV; Shinoda G; Shah SP; Einhorn WS; Takeuchi A; Engreitz JM; Hagan JP; Kharas MG; Urbach A; Thornton JE; Triboulet R; Gregory RI; Altshuler D; Daley GQ. 2011. The Lin28/let-7 Axis Regulates Glucose Metabolism. Cell 147(1):81-94. [PubMed: 21962509] [MGI Ref ID J:177113]
Zong Y; Huang J; Sankarasharma D; Morikawa T; Fukayama M; Epstein JI; Chada KK; Witte ON. 2012. Stromal epigenetic dysregulation is sufficient to initiate mouse prostate cancer via paracrine Wnt signaling. Proc Natl Acad Sci U S A 109(50):E3395-404. [PubMed: 23184966] [MGI Ref ID J:193135]
van Amerongen R; Fuerer C; Mizutani M; Nusse R. 2012. Wnt5a can both activate and repress Wnt/beta-catenin signaling during mouse embryonic development. Dev Biol 369(1):101-14. [PubMed: 22771246] [MGI Ref ID J:187621]
Health & husbandry
Health & Colony Maintenance Information
Animal Health Reports
Production of mice from cryopreserved embryos or sperm occurs in a maximum barrier room, G200.
Pricing and Purchasing
Pricing, Supply Level & Notes, Controls
| Pricing for USA, Canada and Mexico shipping destinations |
|
Cryopreserved
Cryopreserved Mice - Ready for Recovery
Animals Provided
Price (US dollars $) Cryorecovery* $2085.00 At least two mice that carry the mutation (if it is a mutant strain) will be provided. Their genotypes may not reflect those discussed in the strain description. Please inquire for possible genotypes and see additional details below.
Standard Supply
Cryopreserved. Ready for recovery. Please refer to pricing and supply notes on the strain data sheet for further information.
Supply Notes
Cryorecovery - Standard.
Progeny testing is not required.
The average number of mice provided from recovery of our cryopreserved strains is 10. The total number of animals provided, their gender and genotype will vary. We will fulfill your order by providing at least two pair of mice, at least one animal of each pair carrying the mutation of interest. Please inquire if larger numbers of animals with specific genotype and genders are needed. Animals typically ship between 11 and 14 weeks from the date of your order. If a second cryorecovery is needed in order to provide the minimum number of animals, animals will ship within 25 weeks. IMPORTANT NOTE: The genotypes of animals provided may not reflect the mating scheme utilized by The Jackson Laboratory prior to cryopreservation, or that discussed in the strain description. Please inquire about possible genotypes which will be recovered for this specific strain. The Jackson Laboratory cannot guarantee the reproductive success of mice shipped to your facility. If the mice are lost after the first three days (post-arrival) or do not produce progeny at your facility, a new order and fee will be necessary.Cryorecovery to establish a Dedicated Supply for greater quantities of mice
Mice recovered can be used to establish a dedicated colony to contractually supply you mice according to your requirements. Price by quotation. For more information on Dedicated Supply, please contact JAX® Services, Tel: 1-800-422-6423 (from U.S.A., Canada or Puerto Rico only) or 1-207-288-5845 (from any location).
| Pricing for International shipping destinations |
|
Cryopreserved
Cryopreserved Mice - Ready for Recovery
Animals Provided
Price (US dollars $) Cryorecovery* $2710.50 At least two mice that carry the mutation (if it is a mutant strain) will be provided. Their genotypes may not reflect those discussed in the strain description. Please inquire for possible genotypes and see additional details below.
Standard Supply
Cryopreserved. Ready for recovery. Please refer to pricing and supply notes on the strain data sheet for further information.
Supply Notes
Cryorecovery - Standard.
Progeny testing is not required.
The average number of mice provided from recovery of our cryopreserved strains is 10. The total number of animals provided, their gender and genotype will vary. We will fulfill your order by providing at least two pair of mice, at least one animal of each pair carrying the mutation of interest. Please inquire if larger numbers of animals with specific genotype and genders are needed. Animals typically ship between 11 and 14 weeks from the date of your order. If a second cryorecovery is needed in order to provide the minimum number of animals, animals will ship within 25 weeks. IMPORTANT NOTE: The genotypes of animals provided may not reflect the mating scheme utilized by The Jackson Laboratory prior to cryopreservation, or that discussed in the strain description. Please inquire about possible genotypes which will be recovered for this specific strain. The Jackson Laboratory cannot guarantee the reproductive success of mice shipped to your facility. If the mice are lost after the first three days (post-arrival) or do not produce progeny at your facility, a new order and fee will be necessary.Cryorecovery to establish a Dedicated Supply for greater quantities of mice
Mice recovered can be used to establish a dedicated colony to contractually supply you mice according to your requirements. Price by quotation. For more information on Dedicated Supply, please contact JAX® Services, Tel: 1-800-422-6423 (from U.S.A., Canada or Puerto Rico only) or 1-207-288-5845 (from any location).
|
|
|
Standard Supply
Cryopreserved. Ready for recovery. Please refer to pricing and supply notes on the strain data sheet for further information.
Control Information
| Control | ||
|---|---|---|
| 000664 C57BL/6J | ||
| Considerations for Choosing Controls | ||
| Control Pricing Information for Genetically Engineered Mutant Strains. | ||
Payment Terms and Conditions
Terms are granted by individual review and stated on the customer invoice(s) and account statement. These transactions are payable in U.S. currency within the granted terms. Payment for services, products, shipping containers, and shipping costs that are rendered are expected within the payment terms indicated on the invoice or stated by contract. Invoices and account balances in arrears of stated terms may result in The Jackson Laboratory pursuing collection activities including but not limited to outside agencies and court filings.
See Terms of Use tab for General Terms and Conditions
The Jackson Laboratory's Genotype Promise
The Jackson Laboratory has rigorous genetic quality control and mutant gene genotyping programs to ensure the genetic background of JAX® Mice strains as well as the genotypes of strains with identified molecular mutations. JAX® Mice strains are only made available to researchers after meeting our standards. However, the phenotype of each strain may not be fully characterized and/or captured in the strain data sheets. Therefore, we cannot guarantee a strain's phenotype will meet all expectations. To ensure that JAX® Mice will meet the needs of individual research projects or when requesting a strain that is new to your research, we suggest ordering and performing tests on a small number of mice to determine suitability for your particular project.Ordering Information
JAX® Mice
Surgical and Preconditioning Services
JAX® Services
Customer Services and Support
Tel: 1-800-422-6423 or 1-207-288-5845
Fax: 1-207-288-6150
Technical Support Email Form
Terms of Use
Terms of Use
General Terms and Conditions
For Licensing and Use Restrictions view the link(s) below:
- Use of MICE by companies or for-profit entities requires a license prior to shipping.
- Use of MICE by companies or for-profit entities requires a license prior to shipping.
Contact information
General inquiries regarding Terms of UseContracts Administration
| phone: | 207-288-6470 |
| fax: | 207-288-6655 |
JAX® Mice, Products & Services Conditions of Use
"MICE" means mouse strains, their progeny derived by inbreeding or crossbreeding, unmodified derivatives from mouse strains or their progeny supplied by The Jackson Laboratory ("JACKSON"). "PRODUCTS" means biological materials supplied by JACKSON, and their derivatives. "RECIPIENT" means each recipient of MICE, PRODUCTS, or services provided by JACKSON including each institution, its employees and other researchers under its control. MICE or PRODUCTS shall not be: (i) used for any purpose other than the internal research, (ii) sold or otherwise provided to any third party for any use, or (iii) provided to any agent or other third party to provide breeding or other services. Acceptance of MICE or PRODUCTS from JACKSON shall be deemed as agreement by RECIPIENT to these conditions, and departure from these conditions requires JACKSON's prior written authorization.No Warranty
MICE, PRODUCTS AND SERVICES ARE PROVIDED “AS IS”. JACKSON EXTENDS NO WARRANTIES OF ANY KIND, EITHER EXPRESS, IMPLIED, OR STATUTORY, WITH RESPECT TO MICE, PRODUCTS OR SERVICES, INCLUDING ANY IMPLIED WARRANTY OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE, OR ANY WARRANTY OF NON-INFRINGEMENT OF ANY PATENT, TRADEMARK, OR OTHER INTELLECTUAL PROPERTY RIGHTS.
In case of dissatisfaction for a valid reason and claimed in writing by a purchaser within ninety (90) days of receipt of mice, products or services, JACKSON will, at its option, provide credit or replacement for the mice or product received or the services provided.
No Liability
In no event shall JACKSON, its trustees, directors, officers, employees, and affiliates be liable for any causes of action or damages, including any direct, indirect, special, or consequential damages, arising out of the provision of MICE, PRODUCTS or services, including economic damage or injury to property and lost profits, and including any damage arising from acts or negligence on the part of JACKSON, its agents or employees. Unless prohibited by law, in purchasing or receiving MICE, PRODUCTS or services from JACKSON, purchaser or recipient, or any party claiming by or through them, expressly releases and discharges JACKSON from all such causes of action or damages, and further agrees to defend and indemnify JACKSON from any costs or damages arising out of any third party claims.
MICE and PRODUCTS are to be used in a safe manner and in accordance with all applicable governmental rules and regulations.
The foregoing represents the General Terms and Conditions applicable to JACKSON’s MICE, PRODUCTS or services. In addition, special terms and conditions of sale of certain MICE, PRODUCTS or services may be set forth separately in JACKSON web pages, catalogs, price lists, contracts, and/or other documents, and these special terms and conditions shall also govern the sale of these MICE, PRODUCTS and services by JACKSON, and by its licensees and distributors.
Acceptance of delivery of MICE, PRODUCTS or services shall be deemed agreement to these terms and conditions. No purchase order or other document transmitted by purchaser or recipient that may modify the terms and conditions hereof, shall be in any way binding on JACKSON, and instead the terms and conditions set forth herein, including any special terms and conditions set forth separately, shall govern the sale of MICE, PRODUCTS or services by JACKSON.